Antibody Mediated Rejection Market 2026-2033 | Key Innovations, Mergers and Acquisitions, Revenue Opportunities

DataM Intelligence has unveiled its latest report on the "Antibody Mediated Rejection Market Size 2026" delivering powerful insights into key trends, future growth opportunities, and evolving market challenges. Designed to empower smarter decision-making, the report equips businesses with the strategic intelligence needed to stay ahead in a competitive landscape. By blending robust qualitative analysis with data-driven quantitative research, DataM Intelligence offers a well-rounded perspective that helps organizations decode complex market dynamics, unlock new avenues for growth, and seize emerging opportunities in an ever-evolving global market.

Download Free Sample Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/antibody-mediated-rejection-market?sz

The Global Antibody Mediated Rejection Market is expected to reach at a CAGR of 6.3% during the forecast period 2024-2031.

The Antibody Mediated Rejection Market refers to the global industry focused on diagnosing, preventing, and treating antibody-mediated rejection in organ transplant patients. AMR occurs when a recipient's immune system produces antibodies against the transplanted organ, leading to graft dysfunction or failure. The market encompasses therapeutics, diagnostic tools, biologics, and treatment protocols designed to manage AMR. Growth is driven by rising organ transplant procedures, increasing awareness of immunological complications, and advancements in personalized immunotherapy and precision diagnostics.

Unlock Strategic Partnerships in the Growing Antibody Mediated Rejection Market-Connect with Key Industry Leaders Today: https://www.datamintelligence.com/partner-identification-enquiry/antibody-mediated-rejection-market?sz

Recent Industry Developments: United States

✅ March 2026: Regulatory discussions initiated for Imlifidase approval in desensitization, boosting AMR prevention strategies.

✅ February 2026: Biogen expanded clinical programs for Felzartamab, focusing on improved graft survival post-transplant.

✅ January 2026: Phase III trial results for Felzartamab in kidney transplant AMR were anticipated, advancing targeted anti-CD38 therapy options.

Recent Industry Developments: Japan

✅ March 2026: At least three Japanese university hospitals began rolling out AI‐assisted AMR‐risk prediction dashboards that ingest DSA, HLA‐typing, and protocol‐biopsy data, creating opportunities for local tech and med‐tech vendors to supply integrated AMR‐monitoring software to the transplant ecosystem.

✅ February 2026: Japan's Ministry of Health‐linked transplant advisory body revised guidelines on AMR monitoring intervals, formally recommending more frequent DSA and complement‐activation marker testing in the first two post‐transplant years, which is expected to increase routine assay volume and support AMR‐diagnostic market growth.

✅ January 2026: A Japanese pharmaceutical company disclosed a domestic Phase II readout of an antibody‐modulating biologic in heart‐transplant AMR patients, with favorable six‐month graft‐survival and eGFR signals, positioning the therapy as a potential first‐regional AMR‐focused biologic in Japan's small‐but‐high‐value AMR market.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/antibody-mediated-rejection-market?sz

List of the Key Players in the Antibody Mediated Rejection Market:

CSL Behring
Hansa Biopharma
Novartis AG
Talaria Therapeutics
Amgen Inc
Bristol-Myers Squibb
Eli Lilly and Company Inc
Sanofi S.A.
Teva Pharmaceuticals Industries Ltd.
Biogen

How Does Market Research Work in the Antibody Mediated Rejection Market?

Market research for the Antibody Mediated Rejection Market involves systematic data collection and analysis to understand industry trends, customer behavior, and competitive dynamics. It includes primary research such as surveys and interviews, and secondary research from reports, databases, and publications. Analysts evaluate market size, growth drivers, challenges, and opportunities using qualitative and quantitative methods. Insights are validated through expert opinions and forecasting models, enabling businesses to make strategic decisions, identify target segments, and gain a competitive advantage in a rapidly evolving market.

Latest Mergers and Acquisitions of Antibody Mediated Rejection Market:

✅ Biogen's acquisition of Apellis Pharmaceuticals ($5.6 billion): Announced in early April 2026, Biogen agreed to acquire Apellis to bolster its immunology and rare‐disease portfolio, including nephrology‐relevant assets that intersect with antibody‐mediated rejection therapeutic strategies. The deal brings in two FDA‐approved immunology medicines and expands Biogen's kidney disease offerings that can support its AMR‐related pipeline assets (e.g., felzartamab).

✅ GSK's acquisition of RAPT Therapeutics ($2.2 billion): Completed in January 2026, GSK acquired RAPT to gain ozureprubart, a long‐acting anti‐IgE monoclonal antibody in Phase IIb development for food allergy. While this is broader than AMR, it reflects M&A activity in targeted antibody therapeutics intersecting immune‐mediated conditions and expands antibody expertise relevant to immune rejection pathways.

✅ Novartis' agreement to acquire Excellergy (up to $2 billion): Announced in late March 2026, Novartis struck a deal to acquire Excellergy and its next‐generation anti‐IgE antibody therapy. This represents another major pharmaceutical acquisition focused on immunology/antibody therapeutics during the same period, and although predominantly allergic disease‐focused, it signals broader consolidation trends in antibody‐targeted markets connected to immune modulation.

Segments Covered in the Antibody Mediated Rejection Market 2026:

By Treatment: Corticosteroids, Biologics, Immunosuppressants, Plasmapheresis, Others.

By Route of Administration: Injectable, Oral, Others.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis of the Antibody Mediated Rejection Market:

⇥ North America: Leads the market due to advanced infrastructure, strong R&D investments, and early adoption of new technologies.

⇥ Europe: Shows steady growth supported by strict regulations and increasing focus on sustainability initiatives.

⇥ Asia-Pacific: Fastest-growing region driven by rapid industrialization, urbanization, and rising consumer demand in emerging economies.

⇥ Latin America: Experiences moderate growth with expansion in industrial and commercial sectors.

⇥ Middle East & Africa: Gradual market growth supported by increasing investments and improving economic conditions.

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=antibody-mediated-rejection-market

Key Benefits of the Report:

⏩ Comprehensive Market Insights: Gain a deep understanding of market size, trends, and structure.

⏩ Accurate Forecasting: Access reliable future projections to support long-term planning.

⏩ Competitive Analysis: Identify key players, strategies, and positioning in the market.

⏩ Data-Driven Decisions: Make informed business choices backed by verified data.

⏩ Opportunity Identification: Discover emerging trends and untapped growth areas.

⏩ Risk Mitigation: Reduce uncertainties with thorough market evaluation.

⏩ Customer Insights: Understand consumer behavior, preferences, and buying patterns.

⏩ Strategic Planning Support: Align business strategies with market realities.

⏩ Time & Cost Efficiency: Save resources by leveraging ready-to-use research.

⏩ Customization & Expert Validation: Benefit from tailored insights and industry expert analysis.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Antibody Mediated Rejection Market in 2025?
◆ What is the projected growth rate of the Antibody Mediated Rejection Market through 2033?
◆ Who are the key players in the Antibody Mediated Rejection Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.